Focus on Capitalization of Patented Rapid Flow-through Technologies
HALIFAX, Jan. 3 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a global market leader in premium rapid diagnostic solutions,
is pleased to announce the appointment of Richard "Dick" Van Maanen to the
position of Vice President of Global Business Development for the Company.
Mr. Van Maanen is a 25-year veteran of the in vitro diagnostics industry,
and has held sales, marketing, and business development positions with Abbott
Laboratories, ADI Diagnostics, and Calypte Biomedical prior to joining
MedMira. His past responsibilities have focused heavily on distribution and
business development related to the diagnosis of infectious diseases such as
HIV, STDs, and viral hepatitis. Over the course of his career, Mr. Van Maanen
has conducted business all over the world, including Sub-Saharan Africa,
India, and Southeast Asia where the HIV/AIDS crisis is most acute.
"This new executive position for global business development is a
critical piece in our corporate plan to facilitate and fully capitalize our
patented technologies through the execution of out-licensing strategies,
development of new global distribution networks and working closely with
various government agencies such as UNAIDS and USAID. Dick brings a wealth of
domestic and international business experience which is very welcoming news as
MedMira expands its global reach and new products to market," said Hermes
Chan, President and CEO, MedMira.
"MedMira is well known for its rapid flow-through technologies and has
excelled in new product development. Most importantly, it has obtained the key
patent on the rapid flow-through technology platform and is now in a position
to compete with lateral flow technology in the 30 billion dollar global IVD
market," said Dick Van Maanen, VP of Global Business Development, MedMira. "I
am looking forward to securing new exciting business opportunities with
sustainable revenues through our global business strategies."
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals around the world with reliable, rapid diagnosis for diseases such
as HIV and hepatitis C in just three minutes. The company's tests are sold
under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in
global markets. MedMira's rapid HIV test is the only one in the world to
achieve regulatory approvals in Canada, the United States, China and the
In January 2006, MedMira launched the Maple Biosciences division to
develop and commercialize diagnostic instruments based on two revolutionary
biosensor-based technology platforms. The solutions developed by Maple
Biosciences will enable routine laboratory tests to be performed in a matter
of minutes, increasing laboratory automation, streamlining the diagnosis of
multiple conditions and diseases and positioning MedMira to be a leading
participant in the emerging fields of personalized medicine and molecular
diagnostics. For more information visit www.maplebio.com.
MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada with a representative office in China. Maples
Biosciences' labs are located in Toronto, Ontario. For more information visit
MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information:
For further information: Dr. James Smith, Investor Relations & Corporate
Affairs, (902) 450-1588, email@example.com